Introduction {#sec1_1}
============

A distinct clinical entity, now known as papuloerythroderma, was first identified by Ofuji et al. in 1984 \[[@B1]\]. Described in 4 male patients in Japan (a human T-cell lymphotropic virus-1 (HTLV-1)-endemic region), this report found an erythroderma-like eruption and flat-topped papules that spared the skin folds, a finding later termed the "deck-chair sign" \[[@B2]\]. Peripheral eosinophilia and lymphopenia were also observed in some patients. Unfortunately, the HTLV-1 status in these patients was not reported at that time. With an estimated incidence of 1.5 cases per million individuals per year \[[@B3]\], papuloerythroderma of Ofuji (PEO) remains a rare condition. However, multiple factors indicate that PEO is often underdiagnosed and underreported. Many infections, medications, and, more importantly, systemic diseases have been associated with PEO, including cutaneous T-cell lymphomas (CTCL). The relationship between the clinical presentation of PEO and CTCL remains poorly elucidated.

Materials and Methods {#sec1_2}
=====================

The 5 patients reported in this case series provided written informed consent in accordance with the Declaration of Helsinki. Clinical, laboratory, and histopathological data were obtained from the Lymphoma Clinic at the Ottawa Hospital, Canada, and are presented in Table [1](#T1){ref-type="table"} and Figure [1](#F1){ref-type="fig"}.

Case Presentations {#sec1_3}
==================

Case 1 {#sec2_1}
------

A 75-year-old Caucasian male was diagnosed with rapidly progressing Sézary syndrome. The initial skin biopsy was diagnostic of CD30^+^ mycosis fungoides (MF). Notably, during later visits, a re-biopsy of his erythrodermic skin showed nonspecific excoriations, spongiotic changes, and dermal edema with superficial, mixed, acute, and chronic inflammation. Over a period of months, this patient rapidly progressed from 10% body surface area (BSA) patch-plaque disease to 80% BSA involvement, in addition to developing palpable lymph nodes and blood disease with frequent soft-tissue infections. On the physical exam in our clinic, he had classic polygonal, erythematous-brown papules, covering his skin surface and clearly sparing the skin folds (a positive deck-chair sign) (Fig. [1a](#F1){ref-type="fig"}).

Based on recently reviewed diagnostic criteria \[[@B4]\], his laboratory findings confirmed extensive stage IVA~1~ Sézary syndrome disease and showed lactate dehydrogenase (LDH) 718 U/L (reference range, 100--205 U/L); HTLV-1-negative serology; high Sézary cell count, 85% T cells on flow leukemia/lymphoma profile, 80% with CD2^+^, CD3^+^, CD4^+^, CD5^+^, and loss of CD26 and CD7 expression, and a CD4:CD8 ratio of \> 10 (blood stage B~2~ disease); T-cell receptor (TCR) β clonality was confirmed on gene rearrangement analysis by polymerase chain reaction; and bilateral inguinal lymphadenopathy on CT thorax, abdomen, and pelvis. His treatment regimen included topical steroids, topical and systemic antibiotics, isotretinoin, interferon-α, and extracorporeal photophoresis. Later, he developed tumors and acquired large-cell transformation on histology. At that point, extracorporeal photophoresis was discontinued, and the patient was started on brentuximab vedotin.

Case 2 {#sec2_2}
------

A 72-year-old Caucasian female was followed for long-standing stage T1b MF and cutaneous mastocytosis (telangiectasia macularis eruptiva perstans) for over 40 years. Over time, she developed progressive, biopsy-proven, plaque MF, covering 80% of her BSA, but notably sparing her skin folds (Fig. [1b](#F1){ref-type="fig"}). Further investigations revealed leukemic CTCL. Interestingly, while her leukemic CTCL was diagnosed with flow cytometry and TCR clonality studies, repeat skin biopsy of her erythrodermic skin was not diagnostic and only showed a psoriasiform and spongiotic dermatitis with a lymphocytic inflammatory infiltrate. She was then treated with systemic alitretinoin (as bexarotene is not available in Canada) and interferon-α in addition to skin-directed topical therapies.

Laboratory results confirmed stage IVA~1~ CTCL: LDH 196 U/L; HTLV-1/2 antibodies nonreactive; tryptase 5.3 ng/mL (reference range, 3.8--11.4 ng/mL); 38% circulating Sézary cells, 33% abnormal CD4^+^ T cells with loss of CD26 and CD7 expression, and T cells comprising 70% of lymphocytes with a CD4:CD8 ratio of 21: 1 on flow cytometry leukemia/lymphoma profile (blood stage B~2~ disease); β, δ, and γ clonality on TCR gene rearrangement; and bilateral, enlarged, inguinal, and axillary lymph nodes on CT thorax, abdomen, and pelvis.

Case 3 {#sec2_3}
------

An 89-year-old male presented with patch lesions affecting ∼30% of his BSA, consistent with MF (Fig. [1c](#F1){ref-type="fig"}). He had a 2-year history of a nonresolving eruption on the trunk that spared the skin folds. Notably, a skin biopsy was not diagnostic of CTCL, and imaging did not reveal any lymphadenopathy or visceral disease. However, flow cytometry analysis documented the presence of Sézary cells, consistent with blood stage B~2~ disease. Based on these findings, the patient was diagnosed with leukemic CTCL (stage IVA~1~) and was started on multimodality treatment, including topical steroids, narrow-band ultraviolet B phototherapy, isotretinoin, and interferon-α.

Laboratory testing revealed LDH within normal limits and negative HTLV-1 serology. Further investigations demonstrated 44% circulating Sézary cells. Flow cytometry revealed 82% T cells, with 59% of CD4 T cells (44% of lymphocytes) negative for both CD7 and CD26, and a CD4:CD8 ratio of 8.5. β and γ clonality were found on TCR gene rearrangement studies.

Case 4 {#sec2_4}
------

An 82-year-old male with a 5-year history of a pruritic rash that did not respond to topical steroids presented with plaque lesions affecting ∼20% of his skin surface with a positive deck-chair sign (Fig. [1d](#F1){ref-type="fig"}). His MF disease was diagnosed on skin biopsy, and he was found to have a mild blood involvement, based in the TCR β clonality findings in the blood. He did not fulfill any other blood involvement criteria, as recently reviewed elsewhere \[[@B4]\]. He was diagnosed with stage IB (T~2~N~0~B~0b~) MF. He received treatment with topical steroids, narrow-band ultraviolet B phototherapy, and alitretinoin. LDH was found to be normal, and HTLV-1 status was negative. Imaging studies did not reveal lymph-node or visceral involvement.

Case 5 {#sec2_5}
------

An 86-year-old African-Canadian female native of Guyana had a long-standing indolent T1b plaque MF. Her initial biopsy was diagnostic of CTCL and showed mild acanthosis, keratosis, patchy parakeratosis, spongiosis, moderate epidermotropism, atypical lymphocytes forming Pautrier\'s microabscesses, a CD4:CD8 ratio of 6: 1, and loss of CD7 expression in the epidermotropic population. Her plaque MF disease had been treated for 6 years with topical steroids. She then developed a positive deck-chair-sign skin eruption (Fig. [1e](#F1){ref-type="fig"}) and was found to have a leukemic (blood stage B~1a~) disease with high numbers of CD30^+^ cells on flow cytometry. Because the patient was mostly asymptomatic, she was treated with alitretinoin and narrow-band ultraviolet B phototherapy.

This patient had LDH 207 U/L; HTLV-1/2 antibodies nonreactive; 8% circulating Sézary cells, 49% T cells, 84% CD4^+^ T cells with loss of CD26 and CD7 expression, CD8^+^ cells also exhibited a loss of CD7, and co-expression of CD30 in both CD4^+^ and CD8^+^ T cells on flow leukemia/lymphoma cytometry profile; no clonality was detected on gene rearrangement studies.

Discussion {#sec1_4}
==========

In a systematic review published in 2010, Torchia et al. \[[@B5]\] proposed diagnostic criteria and etiological classification of papuloerythroderma (summarized in online suppl. Table [1](#S1){ref-type="supplementary-material"}, [www.karger.com/doi/10.1159/000487473](http://www.karger.com/doi/10.1159/000487473)). Ofuji and others have commented that, while clinically distinct, multiple causative factors including CTCL underlie the development of papuloerythroderma \[[@B6]\]. Two historic case reports are noteworthy for suggesting cutaneous lymphoma as a differential diagnosis of PEO \[[@B7], [@B8]\]. Since that time, numerous case reports of PEO have supported the diagnosis of CTCL based on histological findings alone \[[@B3], [@B9], [@B10], [@B11], [@B12], [@B13], [@B14]\]. The specific diagnosis of folliculotropic MF was made in several cases \[[@B10], [@B12], [@B13], [@B14]\]. Notably, a case report of 3 patients from South Korea observed that PEO might be a variant of early MF, leading these authors to recommend a close follow-up for possible emergence of MF/CTCL once PEO is diagnosed \[[@B10]\]. A systematic review further concluded that "papuloerythroderma-like CTCL" \[[@B5]\] is appropriate nomenclature in cases where the histology under consideration is compatible with CTCL. However, it is very important to note that skin biopsy in erythrodermic MF or Sézary syndrome is often not diagnostic \[[@B15]\], and, hence, flow cytometry and TCR rearrangement studies are necessary before a diagnosis of CTCL can be excluded.

These combined results and previous studies argue that PEO should be viewed as a diagnosis of exclusion and these patients should be monitored carefully for possible emergence of CTCL. Skin biopsy alone is not sufficient to exclude CTCL in these individuals. A positive deck-chair-sign skin eruption may signify systemic/leukemic CTCL. Therefore, these patients warrant a thorough investigation including flow cytometry and TCR clonality studies. Where appropriate, HTLV-1 serology should be ordered in patients originating from HTLV-1-endemic areas, in intravenous drug users, or in individuals at risk of exposures to this virus. We summarize our recommended work-up for these patients in Table [2](#T2){ref-type="table"}.
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![Positive deck-chair-sign (arrows) skin eruption on the trunk of patient 1 (**a**), who was found to have Sézary syndrome, and on the trunks of patients 2--5 (**b--e**), who were diagnosed with mycosis fungoides / cutaneous T-cell lymphoma with evidence of blood involvement.](cde-0010-0046-g01){#F1}

###### 

Patient characteristics in the present case series

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                             Case 1                                                                                                                              Case 2                                                                                                                                 Case 3                                                                                        Case 4                                                                                                                          Case 5
  -------------------------- ----------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------
  Age, years                 75                                                                                                                                  72                                                                                                                                     89                                                                                            82                                                                                                                              86

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Sex                        Male                                                                                                                                Female                                                                                                                                 Male                                                                                          Male                                                                                                                            Female

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Skin phototype             II                                                                                                                                  II                                                                                                                                     II                                                                                            II                                                                                                                              V

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Country of origin          Canada                                                                                                                              Canada                                                                                                                                 Canada                                                                                        Canada                                                                                                                          Guyana

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Skin involvement           80% BSA, plaque lesions with deck-chair-sign skin findings                                                                          80% BSA, patch lesions with deck-chair-sign skin findings                                                                              \~30% BSA, patch lesions with deck-chair-sign skin findings                                   \~20% BSA, plaque lesions with deck-chair-sign skin findings                                                                    75% BSA, plaque lesions with deck-chair-sign skin findings

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Laboratory findings                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 

   LDH\                      High\                                                                                                                               Normal\                                                                                                                                Normal\                                                                                       Normal\                                                                                                                         Normal\
   HTVL-1                    Negative                                                                                                                            Negative                                                                                                                               Negative                                                                                      Negative                                                                                                                        Negative

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Blood involvement                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   

   Sézary count\             80%\                                                                                                                                38%\                                                                                                                                   44%\                                                                                          \-\                                                                                                                             8%\
   Flow cytometry            85% T cells\                                                                                                                        Abnormal T cells with discrete loss of CD26^−^ in 50% of cells\                                                                        82% are T cells\                                                                              Reversed CD4/CD8 ratio of 0.24 observed                                                                                         49% T cells\
                             80% CD7/CD26^−^\                                                                                                                    CD4:CD8 ratio: 21                                                                                                                      59% of CD4 T cells\                                                                                                                                                                                                           84% of CD4^+^ T cells are CD26^−^, CD7^−^, CD30^+^\
                             CD4:CD8 ratio: \>10                                                                                                                                                                                                                                                        (44% of lymphocytes) are negative for both CD7 and CD26\                                                                                                                                                                      CD4:CD8 ratio: 1.3
                                                                                                                                                                                                                                                                                                        CD4:CD8 ratio: 8.5                                                                                                                                                                                                            

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  TCR clonality analysis                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              

   Blood                     TCR β clonality                                                                                                                     TCR β, δ, and γ clonality                                                                                                              TCR β and γ clonality                                                                         TCR β clonality                                                                                                                 Clonality not detected

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Skin biopsy                Diagnostic of MF / Sézary syndrome with CD30^+^ cells                                                                               Skin biopsy initially not diagnostic of MF                                                                                             Skin biopsy not diagnostic of MF                                                              Skin biopsy diagnostic of CTCL                                                                                                  Skin biopsy diagnostic of CTCL

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Imaging studies            Extensive disease                                                                                                                   Bilateral, enlarged, inguinal, and axillary lymph nodes on CT thorax, abdomen, and pelvis                                              No lymphadenopathy or visceral disease                                                        No lymphadenopathy or visceral disease                                                                                          \-

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Treatments                 Topical steroids; antibiotics; isotretinoin; IFN-α; ECP; brentuximab vedotin                                                        Topical steroids; NBUVB; PUVA; alitretinoin; IFN-α                                                                                     Topical steroids; NBUVB; isotretinoin; IFN-α                                                  Topical steroids; NBUVB; alitretinoin                                                                                           Topical steroids; NBUVB; alitretinoin

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Diagnosis                  Sézary syndrome                                                                                                                     Leukemic CTCL                                                                                                                          Leukemic CTCL                                                                                 MF with evidence of blood clonality                                                                                             Leukemic CTCL

                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      

  Clinical disease outcome   Rapidly progressing, T1a to stage IVA disease in months with lymph-node and high blood tumor burden\                                Indolent stage IB patch MF for 4 years, progressed to stage IVA leukemic CTCL with lymph-node involvement as confirmed by a CT scan\   Patient with a 2-year history of nonresolving eruption on the trunk that spared skin folds\   Patient with a 5-year history of itchy rash on the trunk that did not respond to topical steroids and was sparing skin folds\   Indolent stage IB patch/plaque MF for 6 years, progressed to leukemic CTCL with a high proportion of CD30^+^ T cells in the blood
                             He was started on IFN-α, ECP, and isotretinoin\                                                                                     Patient is stable on a multimodality treatment                                                                                         Patient was found to have a leukemic CTCL and was started on multimodality treatment          Patient was found to have T-cell clonality in the blood and was started on alitretinoin in addition to skin-directed therapy    
                             Patient then developed skin tumors (large-cell transformation) at which point ECP was stopped and brentuximab vedotin was started                                                                                                                                                                                                                                                                                                                                                                        
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BSA, body surface area; CTCL, cutaneous T-cell lymphoma; LDH, lactate dehydrogenase; HTVL-1, human T-lymphotropic virus-1; CD, cluster designation; TCR, T-cell rearrangement gene study; NBUVB, narrow-band ultraviolet B phototherapy; PUVA, psoralen with ultraviolet A phototherapy; MF, mycosis fungoides; ECP, extracorporeal photophoresis.

###### 

Proposed work-up to confirm or exclude a "deck-chair sign" or papuloerythroderma of Ofuji-like cutaneous T-cell lymphoma (CTCL) based on present study findings and recent review \[[@B15]\]

  ------------------------------------------------------------------------------------------------
  *History and physical examination*
  Age
  Sex
  Ethnicity and geographic place of origin
  History of presenting illness
  Onset and progression
   Previous and current treatments
   Past medical history
   Family history
  Cutaneous involvement
   Patch, plaque, tumor
   Alopecia (folliculotropic presentation)
   Presence of ectropion
   Deck-chair-sign skin eruption
   Body surface area involvement based on the modified severity-weighted assessment tool (mSWAT)
  Systemic involvement
   Palpable lymph node(s)
   Hepatosplenomegaly
  *Skin biopsy*
  Histopathological examination of skin biopsy consistent with CTCL
  *Blood involvement*
  Flow cytometry
  B~1~ Sézary cell count (\>5%)
  B~2~ Sézary cell count (≥1,000 cells/µL) with a positive clone or
   Increased CD4^+^ or CD3^+^ cells with a CD4:CD8 ratio of ≥10 or
   Increased CD4^+^ cells and CD4^+^CD7^−^ cells ≥40% or
   Increased CD4^+^ cells and CD4^+^CD26^−^ ≥30%
  *T-Cell Clonality*
  T-cell rearrangement in blood and skin (PCR analysis)
  *Other*
  LDH (blood)
  HTLV-1 status (serology)
  Immunophenotype analysis (skin biopsy)
  Presence of large-cell transformation (skin biopsy)
  CD30^+^ positivity (skin biopsy and flow cytometry analysis)
  ------------------------------------------------------------------------------------------------

PCR, polymerase chain reaction; LDH, lactate dehydrogenase; HTLV-1, human T-lymphotropic virus-1.
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